WHAT IS CLAIMED IS:

1. An isolated mammalian cell stably infected with an *Anaplasma* species selected from the group consisting of *A. marginale*, *A. centrale*, *A. bovis*, *A. ovis*, and *A. platys*, wherein said mammalian cell is a nucleated cell.

2. The mammalian cell of claim 1, wherein said cell is infected with *A. marginale*.

3. The mammalian cell of claim 1, wherein said cell is infected with *A. centrale*.

4. The mammalian cell of claim 1, wherein said cell is infected with *A. bovis*.

5. The mammalian cell of claim 1, wherein said cell is infected with *A. ovis*.

6. The mammalian cell of claim 1, wherein said cell is infected with *A. platys*.

7. The isolated mammalian cell of claim 1, wherein said mammalian cell is an endothelial cell.

8. The isolated mammalian cell of claim 7, wherein said cell is selected from the group consisting of a bovine corneal endothelial cell, a rhesus monkey microvascular endothelial cell, a human umbilical vascular endothelial cell, and a human microvascular endothelial cell.

9. An isolated mammalian cell stably infected with an *Anaplasma* species selected from the group consisting of *A. marginale*, *A. phagocytophilum*, *A. centrale*, *A. bovis*, *A. ovis*, and *A. platys*, wherein said mammalian cell is an adherent cell.

10. The mammalian cell of claim 9, wherein said cell is infected with *A. marginale*.

11. The mammalian cell of claim 9, wherein said cell is infected with *A. phagocytophilum*.

12. The mammalian cell of claim 9, wherein said cell is infected with *A. centrale*.

13. The mammalian cell of claim 9, wherein said cell is infected with *A. bovis*.

14. The mammalian cell of claim 9, wherein said cell is infected with *A. ovis*.

15. The mammalian cell of claim 9, wherein said cell is infected with *A. platys*.

16. The isolated mammalian cell of claim 9, wherein said mammalian cell is an endothelial cell.

17. The isolated mammalian cell of claim 5, wherein said cell is selected from the group consisting of a bovine corneal endothelial cell, a rhesus monkey microvascular endothelial cell, a human umbilical vascular endothelial cell, and a human microvascular endothelial cell.

18. An isolated mammalian cell stably infected with *Anaplasma marginale*, wherein said mammalian cell is a nucleated cell.

19. An isolated mammalian cell stably infected with *Anaplasma phagocytophilum*, wherein said mammalian cell is an adherent cell.

20. A method of making a mammalian cell that is stably infected with an *Anaplasma* species selected from the group consisting of A. *marginale, A. centrale, A. bovis, A. ovis,* and *A. platys,* said method comprising contacting a nucleated mammalian cell with said *Anaplasma* species to produce a mammalian cell stably infected with said *Anaplasma* species.

21. The method of claim 20, wherein said cell is infected with *A. marginale.*

22. A method of making a mammalian cell that is stably infected with an *Anaplasma* species selected from the group consisting of *A. marginale, A. phagocytophilum, A. centrale, A. bovis, A. ovis,* and *A. platys,* said method comprising contacting a mammalian adherent cell with said *Anaplasma* species to produce a mammalian cell stably infected with said *Anaplasma* species.

23. The method of claim 22, wherein said cell is infected with *A. phagocytophilum.*

24. A method of making a mammalian cell that is stably infected with *Anaplasma marginale*, said method comprising contacting a nucleated mammalian cell with said *A. marginale* to produce a mammalian cell stably infected with said *A. marginale.*

25. A method of making a mammalian cell that is stably infected with *Anaplasma phagocytophilum*, said method comprising contacting a mammalian adherent cell with said *A. phagocytophilum* to produce a mammalian cell stably infected with said *A. phagocytophilum.*

26. A method for propagating an *Anaplasma* species selected from the group consisting of *A. marginale, A. centrale, A. bovis, A. ovis,* and *A. platys*, said method comprising contacting a nucleated mammalian cell with said *Anaplasma* species to

produce a mammalian cell stably infected with said *Anaplasma* species, and culturing said stably infected mammalian cell.

27. The method of claim 26, wherein said cell is contacted with *A. marginale*.

28. The method of claim 27, wherein said *A. marginale* is obtained from tick cells or red blood cells.

29. The method of claim 26, wherein said mammalian cell is an endothelial cell or a Vero cell.

30. The method of claim 29, wherein said mammalian cell is selected from the group consisting of a bovine corneal endothelial cell, a rhesus monkey microvascular endothelial cell, a human umbilical vascular endothelial cell, and a human microvascular endothelial cell.

31. The method of claim 26, wherein said *Anaplasma* species is propagated for at least 8 weeks.

32. A method for propagating an *Anaplasma* species selected from the group consisting of *A. marginale, A. phagocytophilum, A. centrale, A. bovis, A. ovis,* and *A. platys*, said method comprising contacting a mammalian adherent cell with said *Anaplasma* species to produce a mammalian cell stably infected with said *Anaplasma* species, and culturing said stably infected mammalian cell.

33. The method of claim 32, wherein said cell is contacted with *A. phagocytophilum*.

34. The method of claim 33, wherein said *A. phagocytophilum* is obtained from HL-60 cells or white blood cells.

35. The method of claim 32, wherein said mammalian cell is an endothelial cell or a Vero cell.

36. The method of claim 35, wherein said mammalian cell is selected from the group consisting of a bovine corneal endothelial cell, a rhesus monkey microvascular endothelial cell, a human umbilical vascular endothelial cell, and a human microvascular endothelial cell.

37. The method of claim 32, wherein said *Anaplasma* species is propagated for at least 8 weeks.

38. A method for propagating *Anaplasma marginale*, said method comprising contacting a nucleated mammalian cell with said *A marginale* to produce a mammalian cell stably infected with said *A. marginale,* and culturing said stably infected mammalian cell.

39. A method for propagating *Anaplasma phagocytophilum*, said method comprising contacting a mammalian adherent cell with said *A. phagocytophilum* to produce a mammalian cell stably infected with said *A. phagocytomphilum,* and culturing said stably infected mammalian cell.

40. A method for obtaining an *Anaplasma* species selected from the group consisting of *A. marginale, A. centrale, A. bovis, A. ovis,* and *A. platys*, said method comprising culturing a nucleated mammalian cell stably infected with said *Anaplasma* species, and isolating said *Anaplasma* species from said mammalian cell.

41. The method of claim 40, wherein said cell is infected with *A. marginale.*

42. The method of claim 40, wherein said *Anaplasma* species is an attenuated *Anaplasma* species.

43. A method for obtaining an *Anaplasma* species selected from the group consisting of *A. marginale, A. phagocytophilum, A. centrale, A. bovis, A. ovis,* and *A. platys*, said method comprising culturing a mammalian adherent cell stably infected with said *Anaplasma* species, and isolating said *Anaplasma* species from said mammalian cell.

44. The method of claim 43, wherein said cell is infected with *A. phagocytophilum.*

45. The method of claim 43, wherein said *Anaplasma* species is an attenuated *Anaplasma* species.

46. A method for obtaining *Anaplasma marginale*, said method comprising culturing a nucleated mammalian cell stably infected with said *A. marginale,* and isolating said *A. marginale* from said mammalian cell.

47. A method for obtaining *Anaplasma phagocytophilum*, said method comprising culturing a mammalian adherent cell stably infected with said *A. phagocytophilum,* and isolating said *A. phagocytophilum* from said mammalian cell.